Loading company…
Ordaos uses computational design to develop mini-proteins for potential treatments.
Founded in 2019 and based in New York, Ordaos develops miniPRO proteins and therapies intended to provide treatments for patients. In August 2022, it raised USD 5 million in seed funding led by VTC Ventures, with Route 66 Ventures, Banyan Pacific Capital, IAG Capital Partners and Citta Capital participating. The company planned to use the funding for product development, drug design and discovery, and partner acquisition.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in